Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Psoriatic Arthritis Under HUMIRA (Adalimumab) in Routine Clinical Practice.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 09 Aug 2012
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms ELAN
- Sponsors Abbott Laboratories
- 09 Aug 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 08 Nov 2011 Planned initiation date changed from 1 Oct 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 06 Jul 2011 Planned initiation date changed from 1 May 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.